logo

FDA Calendar

Share
Company Name Regeneron Pharmaceuticals
Drug Name Dupixent (sBLA)
Event Name FDA decision on Dupixent for severe chronic rhinosinusitis with nasal polyps
Event Date 06/26/2019
Outcome Date
Outcome
Drug Status
Rival Drugs
Market Potential
Other Approvals Dupixent is already approved to treat moderate-to-severe atopic dermatitis, and moderate-to-severe asthma
News
Return to FDA Calendar